Drug Trial Radar · NCT00421733
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Last checked: Nov 19, 2026Latest source record: Jan 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
281
Actual
Start
Dec 2006
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) therapy.
Conditions
- Diabetic Nephropathy
- Chronic Kidney Disease
Interventions
Zemplar (paricalcitol ) capsulesDrug
Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
Zemplar (paricalcitol) capsulesDrug
Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
PlaceboDrug
Group 1 - Placebo once daily (two placebo capsules once daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).Time frame: Baseline (within 1 week prior to first treatment) through 24 weeks of treatment
Locations
72 sites in 10 countries. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 862
Phoenix, Arizona
Site Reference ID/Investigator# 864
Fountain Valley, California
Site Reference ID/Investigator# 7291
Yuba City, California
Site Reference ID/Investigator# 853
Hudson, Florida
Site Reference ID/Investigator# 867
Lauderdale Lakes, Florida
Site Reference ID/Investigator# 857
Pembroke Pines, Florida
Site Reference ID/Investigator# 8901
West Palm Beach, Florida
Site Reference ID/Investigator# 7113
Roswell, Georgia
Site Reference ID/Investigator# 2531
Chicago, Illinois
Site Reference ID/Investigator# 3371
Evanston, Illinois
Site Reference ID/Investigator# 869
Indianapolis, Indiana
Site Reference ID/Investigator# 8054
Baton Rouge, Louisiana
Site Reference ID/Investigator# 854
Rockville, Maryland
Site Reference ID/Investigator# 6281
Boston, Massachusetts
Site Reference ID/Investigator# 859
Brooklyn Center, Minnesota
Site Reference ID/Investigator# 7214
Omaha, Nebraska
Site Reference ID/Investigator# 8046
Albany, New York
Site Reference ID/Investigator# 866
Charlotte, North Carolina
Site Reference ID/Investigator# 8039
Greenville, North Carolina
Site Reference ID/Investigator# 8053
Morehead City, North Carolina
Site Reference ID/Investigator# 6626
Winston-Salem, North Carolina
Site Reference ID/Investigator# 7495
Carlisle, Pennsylvania
Site Reference ID/Investigator# 9061
Dallas, Texas
Site Reference ID/Investigator# 8325
Dallas, Texas
Site Reference ID/Investigator# 856
Dallas, Texas
Site Reference ID/Investigator# 7494
San Antonio, Texas
Site Reference ID/Investigator# 774
San Antonio, Texas
Site Reference ID/Investigator# 6316
Düsseldorf, Germany
Site Reference ID/Investigator# 5167
Hanover, Germany
Site Reference ID/Investigator# 6302
Ludwigshafen, Germany
Site Reference ID/Investigator# 6314
Athens, Greece
Site Reference ID/Investigator# 6306
Ioannina, Greece
Site Reference ID/Investigator# 5631
Thessaloniki, Greece
Site Reference ID/Investigator# 6310
Thessaloniki, Greece
Site Reference ID/Investigator# 6312
Bergamo, Italy
Site Reference ID/Investigator# 6303
Brescia, Italy
Site Reference ID/Investigator# 6309
Milan, Italy
Site Reference ID/Investigator# 6210
Modena, Italy
Site Reference ID/Investigator# 6207
Groningen, Netherlands
Site Reference ID/Investigator# 6304
Bydgoszcz, Poland
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.